AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03063970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Rehabilitation
Description: Physiotherapy or Occupational Therapy delivered as routine part of rehabilitation
Study NCT01284634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003 200 mg/day Dose
Description: GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
Study NCT01284634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003 400 mg/day Dose
Description: GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
Study NCT01284634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003 800 mg/day Dose
Description: GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
Study NCT01284634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
Study NCT01271153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours each. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
Study NCT01271153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
Study NCT03379779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 16s RNA sequence of sputum, bronchoalveolar lavage fluid (options), stool
Description: We will check the microbiome in lower respiratory samples (sputum and bronchoalveolar lavage fluid) and stool by using 16S RNA sequencing
Study NCT00645216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Subjects take CP-945,598 alone for 21 days
Study NCT00645216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Subjects take CP-945,598 from Days 1 to 7, then take CP-945,598 and Grapefruit Juice from Days 8 to 21
Study NCT03895437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TOL-3021
Description: TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
Study NCT03895437 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TOL-3021 Placebo
Description: TOL-3021 Placebo
Study NCT02670538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsule one per day orally.
Study NCT00785850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower
Study NCT01732588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZ439 120mg PIB
Description: 120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
Study NCT01732588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg OZ439 caplet
Description: 120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
Study NCT01732588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120mg OZ439 caplet via Enterion capsule
Description: 120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
Study NCT02670538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule one per day orally.
Study NCT00436579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00436579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00436579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT00436579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Study NCT00436579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Ancillary studies
Study NCT00436579 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: assessment of therapy complications
Description: Ancillary studies
Study NCT00436579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00436579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03859375 — intervention group
Intervention type: OTHER
Intervention: microbial skin counts in the disinfection area after paints of skin disinfectants
Description: microbial skin counts in the disinfection area after 2 and 3 paints of skin disinfectants (chlorhexidine in alcohol \[CHX\] and povidone iodine in alcohol \[PI\])
Study NCT02555488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: MB and diode
Study NCT02555488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: diode laser
Study NCT02555488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene blue
Description: Methylene blue and diode laser was used
Study NCT01705275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-8539
Description: ONO-8539
Study NCT01705275 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to ONO-8539 tablet but without active ingedient
Study NCT02621502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa variety 1
Description: On the intervention day, the volunteers will consume the Quinoa Variety 1.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
Study NCT02621502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa variety 2
Description: On the intervention day, the volunteers will consume the Quinoa Variety 2.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
Study NCT02621502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa variety 3
Description: On the intervention day, the volunteers will consume the Quinoa Variety 3.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
Study NCT02621502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa variety 4
Description: On the intervention day, the volunteers will consume the Quinoa Variety 4.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
Study NCT01882595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebulization through the tracheostomy
Description: Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The first session was performed prior to tracheostomy removal. During the first nebulization, subjects inhaled the aerosol through the tracheostomy, cuff inflated and inner cannula removed.
Study NCT01882595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulization through the mouth
Description: Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The second nebulization was performed when the tracheostome was totally scarred. During the second nebulization, subjects inhaled the aerosol a mouth piece and wore a nose clip.
Study NCT03220945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Receive yoga instruction
Study NCT01785628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sarcosine Capsule
Description: Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.
Study NCT01785628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo is dextrin composition.
Study NCT01997320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy resistance exercise and nutrition
Description: Heavy resistance exercise of the lower extremities three times weekly for 12 weeks.
Study NCT01997320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition supplement
Description: Two daily administrations of nutrient supplementation, each containing 20g of milk protein.
Study NCT00767104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silk like Pillowcase
Description: sleep on silk-like pillowcase each night
Study NCT00767104 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cotton Pillowcase
Description: Sleep on placebo cotton pillowcase each night
Study NCT02890914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transvaginal Ultrasound Educational DVD
Description: American Institute of Ultrasound in Medicine, Gynecology: Beginners Only®
Study NCT00321334 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy+Surgery
Description: Docetaxel:75mg/m2 on D1 cycle,3 cycles Carboplatin:AUC=5 on D1 cycle,3 cycles
Study NCT04022889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTERCEPT Treated Platelets
Description: Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) and stored for 7days at 20-24°C with continuous agitation. Samples from the Test component will be processed with either the BEST or the Variant 1 procedure prior to radiolabeling. The radiolabeled autologous Test and Control platelets (approximately 10-30 mL) will be simultaneously administered intravenously into the subject.
Study NCT01912222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXAZOMIB
Study NCT02621502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anhydrous Glucose
Description: On the intervention day, the volunteers will consume the control product.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
Study NCT03694119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenelzine
Description: Phenelzine
Study NCT03694119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tyramine
Description: Tyramine
Study NCT03694119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tyramine
Description: Tyramine
Study NCT03694119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyramine
Description: Tyramine
Study NCT03694119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenelzine placebo
Description: Phenelzine placebo
Study NCT03694119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenelzine placebo
Description: Phenelzine placebo
Study NCT03694119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenelzine placebo
Description: Phenelzine placebo
Study NCT03298607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 months treatment
Study NCT03298607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Serelys PMS
Description: 2 months treatment
Study NCT01727492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidantia
Study NCT03285295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay
Description: For all donor specimens with investigational Alinity s HBsAg and Alinity s HBsAg Confirmatory results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
Study NCT03285295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alinity s HTLV I/II Assay
Description: For all donor specimens with investigational Alinity s HTLV I/II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
Study NCT03285295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alinity s Anti-HCV Assay
Description: For all donor specimens with investigational Alinity s Anti-HCV results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
Study NCT03285295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alinity s HIV Ag/Ab Combo Assay
Description: For all donor specimens with investigational Alinity s HIV Ag/Ab Combo results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
Study NCT03285295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alinity s Anti-HBc Assay
Description: For all donor specimens with investigational Alinity s Anti-HBc results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
Study NCT03285295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alinity s Chagas Assay
Description: For all donor specimens with investigational Alinity s Chagas results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
Study NCT05245604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJO-087
Description: Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily
Study NCT05245604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine ophthalmic solution 0.05%
Description: Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day
Study NCT03015116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Daily foot and ankle stretching protocol
Study NCT03015116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Daily foot and ankle stretching protocol
Study NCT03015116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Daily cryotherapy in conjunction with stretching
Study NCT03015116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Daily cryotherapy in conjunction with stretching
Study NCT03015116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Low Power
Description: Photobiomodulation treatment with 10W power output
Study NCT03015116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation High Power
Description: Photobiomodulation treatment with 25W power output
Study NCT02011256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable loop-recorder
Description: All patients not diagnosed with atrial fibrillation with regular ECG or 72-hour Holter-monitoring will receive an ILR for 3 years.
Study NCT04057911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active NIBS
Description: Cathodal noninvasive brain stimulation will be given for 20 mins.
Study NCT06648044 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Description: Research of therapeutic targets in the frame of nephronophthisis and renal associated ciliopathie
Study NCT04283292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Topical Capsaicin for the treatment of Cannabinoid Hyperemesis Syndrome
Study NCT04283292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo cream that is applied once topically
Study NCT01292421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B antigen peptide
Description: Given PO
Study NCT01292421 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally (PO)
Study NCT01292421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally (PO)
Study NCT01292421 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT01292421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT03694119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ozanimod placebo
Description: ozanimod placebo
Study NCT03694119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ozanimod placebo
Description: ozanimod placebo
Study NCT03593421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic PreImplantation Factor
Description: peptide
Study NCT04504266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWER
Description: This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
Study NCT01918150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titan 2 stents
Description: The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
Study NCT01918150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cobalt-Chromium Bare Metal Stents
Description: The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
Study NCT00497770 — intervention group
Intervention type: DRUG
Intervention: Pemetrexed
Description: Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient
Study NCT04805697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: subjects drank 50 ml , 1 bottle a day for 8 week
Study NCT04805697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fermented grape drinks
Description: subjects drank 50 ml , 1 bottle a day for 8 week
Study NCT03129191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive bone conduction hearing aid A
Description: The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an elastic headband.
Study NCT03129191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive bone conduction hearing aid B
Description: The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.
Study NCT03613558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is an alpha-2 agonist that provides both sedation and analgesia
Study NCT03613558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline solution
Study NCT01649648 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cord blood
Description: Baby's own umbilical cord blood
Study NCT02189018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Exercise
Description: Active exercise on a treadmill
Study NCT02189018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation
Study NCT02189018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss and active exercise
Description: Weight loss and active exercise on a treadmill